Evidence of Sample Use Among New Users of Statins
- 1 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 52 (9) , 773-780
Abstract
Background: Epidemiologic studies of prescription medications increasingly rely on large administrative health care databases. These data do not capture patients' use of medication samples. This could potentially bias studies of short-term effects where date of initiation may be inaccurate. Objectives: To assess the extent of sample use among patients initiating statin therapy. Research Design: Retrospective cohort of patients who filled a first prescription for a statin after at least 6 months of statin-free period in 2007-2010. Low-density lipoprotein (LDL) values obtained within the 15 days preceding the first prescription were analyzed using a 2-component Gaussian mixture model to look for evidence of prior treatment. Subjects: A total of 26,033 statin initiators with at least 1 LDL laboratory result within the 15 days preceding the prescription fill. Measures: Estimators for the proportion of patients filling a new prescription already on treatment. Results: Among 9256 patients filling a branded statin, LDL distribution was bimodal, consisting of 2 Gaussian distributions: one, which made up 13.4% of the total population, had much lower LDL values (mean = 71.8 mg/dL) compared with the second (mean = 148.0 mg/dL), suggesting drug use before first dispensed prescription. Among 16,777 patients filling a generic statin, LDL levels were substantially higher with no evidence of bimodality that would suggest prior sample use. Conclusions: These results provide indirect evidence that the initial period of branded medication use may often be missed when using pharmacy claims data to define drug initiation. Further research is needed to examine approaches to better identify incident medication use when assessing short-term effects.Keywords
This publication has 35 references indexed in Scilit:
- Promotion of Prescription Drugs to Consumers and Providers, 2001–2010PLOS ONE, 2013
- Use of administrative claims data for comparative effectiveness research of rheumatoid arthritis treatmentsArthritis Research & Therapy, 2011
- Four-Dollar Generics — Increased Accessibility, Impaired Quality AssuranceNew England Journal of Medicine, 2010
- Completeness of retail pharmacy claims data: Implications for pharmacoepidemiologic studies and pharmacy practice in elderly patientsClinical Therapeutics, 2009
- Time-modified ConfoundingAmerican Journal of Epidemiology, 2009
- Characteristics of Recipients of Free Prescription Drug Samples: A Nationally Representative AnalysisAmerican Journal of Public Health, 2008
- Studying Prescription Drug Use and Outcomes With Medicaid Claims DataMedical Care, 2007
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)The American Journal of Cardiology, 2003
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995